Platinum Resistant Ovarian Cancer (PROC) - Market Insights, Epidemiology, and Market Forecast - 2034

Key Highlights:

• The lack of reliable biomarkers has hindered progress in treating PROC. The validation of FRa as a predictive biomarker for ELAHERE (mirvetuximab soravtansine) marks a shift toward targeted, biomarker-driven therapies. As the only ADC evaluated in a pivotal PROC trial, mirvetuximab leverages FRa overexpression in ovarian tumors to deliver cytotoxic payloads selectively, offering a promising therapeutic strategy with improved precision and reduced off-target effects.
• Primary PROC is associated with a particularly poor prognosis, driven by intrinsic resistance to available therapies, limited clinical trial representation, and a lack of validated biomarkers to guide treatment.
• Clinical trials in PROC often exclude heavily pretreated or comorbid patients, limiting their relevance to real-world settings and potentially overstating treatment efficacy.
• Relapsed advanced ovarian cancer is typically incurable, highlighting the urgent need for more effective first-line treatments. High relapse rates suggest current therapies fail to eliminate micrometastatic disease or address tumor heterogeneity.
• In July 2025, ELAHERE became the first FRa-targeted antibody-drug conjugate approved in the UK for treating adults with platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
• The development of secondary platinum resistance in initially sensitive patients highlights the adaptive evolution of ovarian cancer, where each recurrence is marked by shorter progression-free intervals and increasing treatment resistance. This pattern reflects the selective pressure of repeated therapy, driving the emergence of resistant tumor clones and signaling the need for proactive, biology-driven treatment strategies.
• PARP inhibitor monotherapy has limited efficacy in BRCA wild-type PROC and is not routinely recommended. However, its ability to modulate the tumor microenvironment and enhance immunogenicity supports its potential role in combination with immunotherapies.
• Mirvetuximab soravtansine and weekly paclitaxel are among the most active agents in PROC and are preferred treatment options in the US for patients without prior exposure or contraindications.
• The pipeline for PROC is growing, with Corcept Therapeutics (relacorilant), Advenchen Laboratories (catequentinib), Regeneron Pharmaceuticals (ubamatamab), Laekna Therapeutics (afuresertib), and others in clinical development.

DelveInsight's "Platinum Resistant Ovarian Cancer (PROC) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of PROC, historical and forecasted epidemiology as well as PROC market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The PROC market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM PROC market size from 2020 to 2034. The report also covers current PROC treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Platinum Resistant Ovarian Cancer (PROC): Understanding and Treatment Algorithm

Ovarian Cancer Overview

Ovarian cancer represents only about 3% of all cancers in women, yet it ranks as the fifth leading cause of cancer-related death, following lung, breast, colorectal, and pancreatic cancers. It can originate from different types of cells within the ovary: the epithelial cells that cover the ovary, the germ cells that produce eggs, or the stromal cells responsible for hormone production and structural support. Despite its relatively low incidence, ovarian cancer has the highest mortality rate among gynecologic malignancies and is often referred to as a "silent killer." This is largely due to its tendency to develop without noticeable symptoms and the absence of effective screening methods, which means approximately 75% of cases are diagnosed at an advanced stage. While less common than breast cancer, ovarian cancer is nearly three times more deadly. Platinum-based chemotherapy remains a cornerstone of treatment. However, most patients eventually experience relapse. PROC is defined by disease progression within six months of completing platinum therapy, signaling a major therapeutic challenge due to the development of resistance to this critical drug class.

Ovarian Cancer Diagnosis

The symptoms of ovarian cancer are often vague and nonspecific, making early detection difficult. They can easily be mistaken for symptoms of more common, less serious conditions. As a result, noticeable symptoms typically emerge only in the later stages of the disease (stage III or IV). Current screening approaches include transvaginal ultrasound (TVU), physical examination, and measurement of serum biomarkers, primarily CA125. However, CA125 has limited sensitivity in detecting early-stage disease, prompting the investigation of alternative biomarkers such as cancer antigen 19-9 (CA19-9) and human epididymis protein 4 (HE4), which may be useful for identifying specific ovarian cancer subtypes. Advances in imaging techniques are enhancing diagnostic accuracy. These include the use of Doppler ultrasound to improve TVU precision, high-resolution MRI, and PET/CT scans that combine structural and functional imaging data. Newer hysteroscopy-based methods, such as those using Falloposcope devices, aim to collect cytological samples from the fallopian tubes and hold promise for early detection. The field of biomarker discovery is also rapidly evolving. Novel candidates, including microRNAs (miRNAs), cancer-associated microbiota, autoantibodies, extracellular vesicles, and metabolomic profiles, are showing potential to improve diagnostic strategies. Combined with improvements in imaging technologies, these innovations may significantly enhance the ability to detect ovarian cancer at earlier, more treatable stages.

Platinum Resistant Ovarian Cancer (PROC) Treatment

Current management involves non-platinum chemotherapies such as paclitaxel, pegylated liposomal doxorubicin, topotecan, gemcitabine, or etoposide, often combined with the anti-angiogenic agent bevacizumab to improve progression-free survival. PARP inhibitors (olaparib, niraparib, rucaparib, veliparib) offer clinical benefit in patients with BRCA mutations or homologous recombination deficiency, and their efficacy may be enhanced when combined with antiangiogenic agents like bevacizumab or anlotinib. Novel therapies targeting cell cycle checkpoints, such as CHK1 and WEE1 inhibitors, have shown promising response rates, particularly in p53-mutated or BRCA wild-type disease. Epigenetic modulators, including DNMT inhibitors like guadecitabine and decitabine, can resensitize tumors to platinum agents and enhance immunotherapy responses. Immune checkpoint inhibitors alone have limited benefit in PROC, but combination strategies, such as PARP inhibitors with ICIs, or ICIs with antiangiogenic agents or chemotherapy, have demonstrated improved disease control. Additionally, targeting copper homeostasis with agents like trientine, tranilast, and theaflavin-3,3'-digallate may restore platinum sensitivity by modulating transporter expression. Together, these approaches reflect a shift toward biomarker-driven, combination-based strategies aimed at overcoming resistance and improving outcomes in PROC.

Platinum Resistant Ovarian Cancer (PROC) Epidemiology

The PROC epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of ovarian cancer, site-specific incident cases of ovarian cancer, stage-specific incident cases of ovarian cancer, mutation-specific incident cases of ovarian cancer, line-wise treated cases of ovarian cancer, and total incident cases of platinum resistant ovarian cancer in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.

• Throughout the 7MM, the US accounted for the maximum cases of ovarian cancer with around 20,000.
• Among EU4 and the UK, the UK had the highest number of cases of LGSOC, followed by Germany, whereas Spain was at the bottom of the ladder.
• As per analysis, 25% of patients diagnosed with ovarian cancer have a primary platinum resistance, making it prevalent in approximately 50,000 patients worldwide.
• Among type-specific cases of ovarian cancer, serous ovarian cancer accounted for the maximum number of cases, throughout the 7MM.
• Approximately 80% of patients with advanced ovarian cancer and 20% with early-stage disease experience recurrence after first-line therapy.

Platinum Resistant Ovarian Cancer (PROC) Drug Chapters

The drug chapter segment of the PROC report encloses a detailed analysis of PROC marketed drugs. It also deep dives into PROC pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Marketed Drugs

ELAHERE (mirvetuximab soravtansine): AbbVie

ELAHERE is a mAb (a type of protein) that has been designed to recognize and attach to folate receptors on the surface of cancer cells. When mirvetuximab soravtansine binds to the FRa receptor, it is taken up by the cell, where it releases a chemotherapy medicine called DM4. Once inside, DM4 kills the cancer cells by interfering with their ability to divide and grow.

• In March 2025, AbbVie announced the final analysis of the confirmatory Phase III MIRASOL trial evaluating the efficacy and safety of ELAHERE in women with folate receptor alpha (FRa)-positive PROC compared to chemotherapy.
• In November 2024, AbbVie announced the European Commission had granted marketing authorization for ELAHERE for the treatment of adult patients with FRa positive, platinum-resistant HGS EOC, FTC, or PPC who have received one to three prior systemic treatment regimens.
• In March 2024, AbbVie announced that the US FDA had granted full approval for ELAHERE for the treatment of FRa-positive, platinum-resistant EOC, FTC or PPC patients treated with up to three prior therapies.

Emerging Drugs

Relacorilant (CORT125134): Corcept Therapeutics

Relacorilant is a selective cortisol modulator that binds to the Glucocorticoid Receptor (GR) but does not bind to the body's other hormone receptors. Corcept is studying relacorilant in a variety of serious disorders, including ovarian, adrenal, and prostate cancer and Cushing's syndrome.

• In June 2025, Corcept Therapeutics shared data from its pivotal Phase III ROSELLA trial of relacorilant plus nab-paclitaxel in patients with PROC in a late-breaking oral presentation at the ASCO 2025 Annual Meeting.
• In April 2025, Corcept Therapeutics announced the start of BELLA, a Phase II trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in patients with PROC.

Catequentinib (Anlotinib/AL3818): Advenchen Laboratories

Anlotinib is an innovative oral RTK inhibitor that targets VEGFR-2 and -3, FGFR1-4, PDGFR-a and -B, c-Kit, and Ret. By doing so, it effectively suppresses tumor growth and angiogenesis. Currently the drug is being evaluated in the Phase III for platinum-sensitive or platinum-resistant recurrent or metastatic ovarian cancer.

In February 2024, Advenchen Laboratories announced that L3818-US-002 Japan run-in cohort with three patients of AL3818-US-002 global PROC Phase III study has completed DLT evaluation within 6 months and started the close out process.

Drug Class Insights

The drug classes include GR antagonists, RTK inhibitor, Adenosine triphosphate competitive AKT inhibitor, and others.

Glucocorticoid receptor (GR) antagonists target stress-mediated survival pathways in cancer cells by blocking GR-driven transcription of anti-apoptotic and pro-survival genes. In PROC, GR signaling is associated with reduced chemotherapy sensitivity and enhanced tumor resilience. Relacorilant, a selective GR modulator, inhibits this pathway without intrinsic agonist activity, thereby restoring apoptotic response to chemotherapy. Clinical data, including from the ROSELLA trial, show that relacorilant combined with nab-paclitaxel improves progression-free survival versus chemotherapy alone, highlighting GR antagonism as a rational strategy to overcome chemoresistance in PROC.

Platinum Resistant Ovarian Cancer (PROC) Market Outlook

The therapeutic landscape for PROC remains complex and heavily unmet, with modest response rates to standard single-agent chemotherapies driving a strong push toward targeted and combinatorial strategies. Established agents such as PARP inhibitors and anti-angiogenic therapies continue to play a foundational role; however, recent momentum is centred on biomarker-driven treatments and novel mechanisms of action. The full FDA approval of ELAHERE in 2024 for folate receptor alpha (FRa)-positive PROC marked a major advancement, demonstrating both progression-free and overall survival benefits over chemotherapy and reinforcing the importance of molecular diagnostics in treatment selection. In parallel, investigational agents such as relacorilant (CORT125134) have shown meaningful clinical benefit when combined with nab-paclitaxel, while catequentinib (anlotinib), a multi-targeted tyrosine kinase inhibitor, is under evaluation for resistant disease. Immunotherapy-based approaches, including ubamatamab (REGN4018), a MUC16-directed bispecific T-cell engager +- cemiplimab, and the AKT inhibitor afuresertib (LAE002) in combination with paclitaxel, further illustrate the field's shift toward multi-pathway, biomarker-guided regimens.

Platinum Resistant Ovarian Cancer (PROC) Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025-2034. The landscape of PROC treatment has experienced a profound transformation with the uptake of novel drugs. These innovative therapies are redefining standards of care. Furthermore, the increased uptake of these transformative drugs is a testament to the unwavering dedication of physicians, oncology professionals, and the entire healthcare community in their tireless pursuit of advancing cancer care. This momentous shift in treatment paradigms is a testament to the power of research, collaboration, and human resilience.

Key Highlights:

• In July 2025, Corcept Therapeutics announced submission of a new drug application (NDA) to the US FDA for its proprietary, selective cortisol modulator, relacorilant, to treat patients with PROC.
• In April 2025, Mural Oncology announced that following review of data from its Phase II ARTISTRY-6 trial in melanoma and previously announced results from the Phase III ARTISTRY-7 trial in PROC, the company is discontinuing all clinical development of nemvaleukin alfa and plans to immediately commence the exploration of strategic alternatives focused on maximizing shareholder value.
• In March 2025, Sutro announced completion of a strategic portfolio review resulting in the prioritization of its wholly-owned next-generation ADC programs. While Sutro will not continue the development of luveltamab tazevibulin (luvelta; being developed for PROC) on its own, it remains open to partnership opportunities.

Platinum Resistant Ovarian Cancer (PROC) Pipeline Development Activities

The report provides insights into therapeutic candidates in Phase III, Phase II, and Phase I/II. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for PROC emerging therapy.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on PROC evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including oncologists, radiation oncologists, surgical oncologists, and others.

Delveinsight's analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 7+ KOLs in the 7MM. Centers such as - Dana-Farber Cancer Institute, Vall d'Hebron Institute of Oncology, European Institute of Oncology, Memorial Sloan Kettering Cancer Center, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, University of Oxford, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or PROC market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event- free survival, one of the most crucial primary outcome measures is event-free survival and overall survival.

Further, the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and this clearly explains the drugs side effects in the trials. In addition, the scoring is also based on the probability of success and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of PROC, explaining its causes, signs, symptoms, pathogenesis, and currently used therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• Additionally, an all-inclusive account of the emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the PROC market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM PROC market.

Platinum Resistant Ovarian Cancer (PROC) Report Insights

• Patient Population
• Therapeutic Approaches
• PROC Pipeline Analysis
• PROC Market Size and Trends
• Existing and Future Market Opportunity

Platinum Resistant Ovarian Cancer (PROC) Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• PROC Epidemiology Segmentation
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

Platinum Resistant Ovarian Cancer (PROC) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT Analysis and Conjoint Analysis)

FAQs:

• What was the PROC market size, the market size by therapies, market share (%) distribution in 2024, and what would it look like by 2034? What are the contributing factors for this growth?
• What are the pricing variations among different geographies for approved therapies?
• What can be the future treatment paradigm PROC?
• What are the disease risks, burdens, and unmet needs of PROC? What will be the growth opportunities across the 7MM concerning the patient population with PROC?
• What are the current options for the treatment of PROC? What are the current guidelines for treating PROC in the US, Europe, and Japan?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitations of existing therapies?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the PROC market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the Analyst view section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of current therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.